Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
Authors:
- Paul R GorryPGPaul R Gorry
- Dale A McPheeDMDale A McPhee
- Erin VerityEVErin Verity
- Wayne B DyerWDWayne B Dyer
- Steven L WesselinghSWSteven L Wesselingh
- Jennifer LearmontJLJennifer Learmont
- John S SullivanJSJohn S Sullivan
- Michael RocheMRMichael Roche
- John J ZaundersJZJohn J Zaunders
- Dana GabuzdaDGDana Gabuzda
- Suzanne M CroweSCSuzanne M Crowe
- John MillsJMJohn Mills
Open Access
- 1 January 2007
- journal article
- Published by Springer Nature in Retrovirology
- Vol. 4 (1) , 66
Abstract
In efforts to develop an effective vaccine, sterilizing immunity to primate lentiviruses has only been achieved by the use of live attenuated viruses carrying major deletions in nef and other accessory genes. Although live attenuated HIV vaccines are unlikely to be developed due to a myriad of safety concerns, opportunities exist to better understand the correlates of immune protection against HIV infection by studying rare cohorts of long-term survivors infected with attenuated, nef-deleted HIV strains such as the Sydney blood bank cohort (SBBC). Here, we review studies of viral evolution, pathogenicity, and immune responses to HIV infection in SBBC members. The studies show that potent, broadly neutralizing anti-HIV antibodies and robust CD8+ T-cell responses to HIV infection were not necessary for long-term control of HIV infection in a subset of SBBC members, and were not sufficient to prevent HIV sequence evolution, augmentation of pathogenicity and eventual progression of HIV infection in another subset. However, a persistent T-helper proliferative response to HIV p24 antigen was associated with long-term control of infection. Together, these results underscore the importance of the host in the eventual outcome of infection. Thus, whilst generating an effective antibody and CD8+ T-cell response are an essential component of vaccines aimed at preventing primary HIV infection, T-helper responses may be important in the generation of an effective therapeutic vaccine aimed at blunting chronic HIV infection.Keywords
This publication has 100 references indexed in Scilit:
- Viral Phenotypes and Antibody Responses in Long-Term Survivors Infected with Attenuated Human Immunodeficiency Virus Type 1 Containing Deletions in thenefand Long Terminal Repeat RegionsJournal of Virology, 2007
- HIV VACCINESAnnual Review of Immunology, 2006
- RETRACTED ARTICLE: Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cellsNature Immunology, 2006
- In vivo replication kinetics of a nef-deleted strain of HIV-1AIDS, 2005
- Molecular virology and immunology of HIV infectionJournal of Allergy and Clinical Immunology, 2002
- Characterization of Immune Escape Viruses from a Macaque Immunized with Live-Virus Vaccine and Challenged with Pathogenic SHIV KU-1AIDS Research and Human Retroviruses, 2000
- T cell depletion in HIV-1 infection: how CD4+ T cells go out of stockNature Immunology, 2000
- Pathogenic Conversion of Live Attenuated Simian Immunodeficiency Virus Vaccines Is Associated with Expression of Truncated NefJournal of Virology, 2000
- Augmented Serum Neutralizing Activity against Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Isolates in Two Groups of HIV‐1‐Infected Long‐Term NonprogressorsThe Journal of Infectious Diseases, 1997
- Absence of Intact nef Sequences in a Long-Term Survivor with Nonprogressive HIV-1 InfectionNew England Journal of Medicine, 1995